Active substance
Tenoxicam
- SFDA 7
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TILCOTIL TAB 20MG | 20 mg | Tablet · Oral use | 10 Blister | SAR 21.30 | NCE · Prescription | MEDA PHARMA GmbH & Co KG | Valid |
| TILCOTIL TAB 20MG | 20 mg | Tablet · Oral use | 30 Blister | SAR 56.10 | NCE · Prescription | MEDA PHARMA GmbH & Co KG | Valid |
| TENOX 20MG CAPS | 20 mg | Capsule · Oral use | 8 Blister | SAR 10.35 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Withdrawn by MAH · Not Marketed |
| TILCOTIL 20MG VIAL | 20 mg | Injection · Intramuscular use | 5 Ampoule | SAR 31.85 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| TILCOTIL SUPP 20MG | 20 mg | Suppository · Rectal use | 10 Blister | SAR 34.05 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| TILCOTIL TAB 20MG | 20 mg | Tablet · Oral use | 10 Blister | SAR 21.30 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
| TILCOTIL TAB 20MG | 20 mg | Tablet · Oral use | 30 Blister | SAR 56.10 | NCE · Prescription | ROCHE | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; LOW BACK PAIN; MENSTRUAL DISORDERS; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.